Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
BioStem Technologies Inc (BSEM)
OTHER OTC:BSEM
Holding BSEM?
Track your performance easily
Earnings Data
Report Date
Apr 07, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
0.37Last Year’s EPS
0.2Same Quarter Last Year
Based on 0 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 24, 2021
|% Change Since: -35.68%
|Next Earnings Date:Apr 05, 2021
Earnings Call Sentiment|Positive
The earnings call reflects a strong performance with record-breaking revenue and strategic advancements. Despite increased operating expenses and ongoing challenges with Medicare reimbursement policies, the overall outlook remains positive with significant milestones achieved and a promising future trajectory.Company Guidance
During the earnings call for Q3 2024, BioStem Technologies provided optimistic guidance, reporting a record revenue of $82.6 million and an adjusted EBITDA of $9.9 million, marking it the third consecutive quarter of record-setting growth. The company highlighted its strong financial position with a cash balance of $14.6 million and a gross margin of 95%, showcasing operational efficiency. BioStem's net revenue for the first nine months of 2024 reached $199 million, driven by the robust performance of their AmnioWrap2 product. The company is actively engaging with CMS on Medicare reimbursement policies and is preparing for the Q4 2024 launch of VENDAJE AC. Additionally, BioStem is conducting clinical trials and has filed for uplisting to NASDAQ, aiming to enhance visibility and access to a broader investor base. The company is focused on expanding market access and improving patient outcomes, projecting further growth and innovation in the coming quarters.Record-Breaking Revenue and Growth
BioStem Technologies posted revenue of $82.6 million in Q3 2024, marking their third consecutive quarter of record-setting growth. Net revenue for the first 9 months of 2024 reached $199 million, highlighting continued momentum.
Strong Financial Performance
Adjusted EBITDA for Q3 was $9.9 million, with a cash position improved to $14.6 million. Gross margin remained solid at 95%, reflecting operational excellence.
Clinical and Strategic Advancements
BioStem received IRB approval for two major clinical studies and enrolled first patients in clinical trials evaluating BioRetain allografts. Positive results were published in an International Moon Journal.
Uplisting and Market Strategy
Filed Form 10 with the SEC and submitted an application for uplisting to NASDAQ. This strategic move is expected to enhance visibility and accessibility to a broader investor base.
---
BSEM Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
BSEM Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 12, 2024 | $24.72 | $24.98 | +1.05% |
| Aug 12, 2024 | $12.50 | $13.55 | +8.40% |
| May 14, 2024 | $9.27 | $9.70 | +4.64% |
| Apr 01, 2024 | $15.50 | $13.23 | -14.65% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does BioStem Technologies Inc (BSEM) report earnings?
BioStem Technologies Inc (BSEM) is schdueled to report earning on Apr 07, 2025, TBA Not Confirmed.
What is BioStem Technologies Inc (BSEM) earnings time?
BioStem Technologies Inc (BSEM) earnings time is at Apr 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BSEM EPS forecast?
BSEM EPS forecast for the fiscal quarter 2024 (Q4) is 0.37.
---